

GIOSTAR

CLINICAL EVIDENCE DOSSIER · PHYSICIAN REFERENCE · MMXXVI

Clinical *evidence.*

Documented outcomes across skin,
wound healing, and tissue restoration.

A companion reference document to the CUPRENE Beauty Dossier.
Intended for physicians, researchers, and clinical review only.
Contains graphic clinical imagery — viewer discretion advised.

GLOBAL INSTITUTE OF STEM CELL THERAPY & RESEARCH

SAN DIEGO, CALIFORNIA · BIO-ACTIVE MOLECULES (BAM) PROGRAM

GIOSTAR · CLINICAL EVIDENCE

THE SCIENCE

Bio-Active Molecules *released by stem cells.*

Adult Human Stem Cell-Derived Molecules (AHSDM) are the signaling agents — growth factors, anti-inflammatory cytokines, exosomes, and peptides — secreted by cultivated stem cells. GIOSTAR's Bio-Active Molecule (BAM) program captures these molecules cell-free and DNA-free, delivering them topically for regenerative, restorative, and anti-inflammatory applications.

The molecules are responsible for up to 80% of the healing and repair capacity of stem cells themselves — without the regulatory complexity, cost, or immune considerations of cellular therapies. GIOSTAR has developed clinical evidence across dermatological, wound-healing, and tissue-restoration applications.

PROGRAM HIGHLIGHTS

AHSDM cream	40-subject study	Return rate	vs. 5 leading serums
Well tolerated non-comedogenic	Ages 35–80 6-week protocol	0.05% across 2,000 units	+31% or better across 8 measures

Wrinkle *reduction.*

Progressive reduction in facial wrinkle depth with topical AHSDM application. Sequential clinical photography documents change at baseline, 8 weeks, and 6 months of continued use.

PROTOCOL

Nightly topical application of BAM cream. Sequential photography under identical lighting and camera settings.

AREA

Facial — periorbital, perioral, and forehead

DURATION

6 months



BASELINE



8 WEEKS



6 MONTHS

Accelerated *wound closure.*

Direct topical AHSDM application to a soft-tissue wound. Documented progression at baseline, 36 hours, and 4 weeks post-initial treatment. Substantial reduction in erythema and re-epithelialization visible in sequential imaging.

PROTOCOL

Direct topical application to wound bed. Documented healing timeline under identical clinical lighting.

AREA

Soft-tissue wound

DURATION

4 weeks



BASELINE



36 HOURS



4 WEEKS

Inflammation *resolution.*

A GIOSTAR case study, "Mesenchymal Stem Cell Conditioned Media Ameliorate Psoriasis Vulgaris," published in Case Reports in Dermatological Medicine, documented resolution of psoriatic plaques following topical AHSDM protocol. Baseline and 6-month follow-up

AREA

Psoriatic plaques — extremity

DURATION

6 months



BASELINE



6 MONTHS

Follicular *regeneration.*

Subject with complete hair loss of 2 years' standing. Prior treatments with Minoxidil and standard therapies failed. AHSDM delivered by direct scalp infusion and IV administration. Documented hair growth observed at 3 months of therapy.

PROTOCOL

Direct scalp infusion combined with IV administration of AHSDM. Sequential imaging under standardized conditions.

AREA

Scalp — alopecia totalis

DURATION

12 weeks



BASELINE



8 WEEKS



12 WEEKS

US and EU compliance, *in process and on record.*

UNITED STATES	EUROPEAN UNION
FD&C Act §201(i) — cosmetic drug product compliant	CPNP (Cosmetic Product Notification Portal) — in process
CFR Title 21 §700.11 & §700.13 — cosmetic drug product	Regulation (EU) No. 655/2013 — claim criteria observed
FDA Form 2511 — Cosmetic Establishment (in process)	Full technical dossier and safety assessment on file
FDA Form 2512 — Ingredient Statement (in process)	SCCS-reviewed ingredients across formulation
CIR-reviewed ingredients across formulation	Safety assessor report included in technical dossier

Prior FDA collaboration on Expanded Access for Compassionate Use in COVID-19 stem-cell therapy expedite regulatory processing for BAM registration.

GIOSTAR · CLINICAL EVIDENCE

To make the most
advanced cellular science
available in a bottle.

The vision that founded GIOSTAR twenty years ago.

CUPRENERX.COM

SALES@AMINODEVELOPMENT.COM · SAN DIEGO

For physician and clinical reference only. Not intended as medical advice. Clinical outcomes shown are documented